Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

• Fariba Ahmadizar,

  Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands

  ⨯
• N. Charlotte Onland-Moret,

  Affiliation Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands

  ⨯
• Anthonius de Boer,

  Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands

  ⨯
• Geoffrey Liu,

  Affiliations Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital/University Health Network and University of Toronto, Toronto, Ontario, Canada, Division of Epidemiology, Dalla Lana School of Public Health, Toronto, Ontario, Canada

  ⨯
• Anke H. Maitland-van der Zee

  * E-mail: A.H.Maitland@uu.nl

  Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands

  ⨯